Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification

British Journal of Cancer

Volumn 106, Issue 5, 2012, Pages 916-922

  Betof, A S ^a   Rabbani, Z N ^a   Hardee, M E ^a   Kim, S J ^b   Broadwater, G ^a   Bentley, R C ^a   Snyder, S A ^a   Vujaskovic, Z ^a   Oosterwijk, E ^c   Harris, L N ^d   Horton, J K ^a   Dewhirst, M W ^a   Blackwell, K L ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Korea University Ansan Hospital   (South Korea)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

breast cancer; CA IX; doxorubicin; hypoxia

Indexed keywords

BIOLOGICAL MARKER; CARBONATE DEHYDRATASE IX; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; ENZYME ACTIVITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CARBONIC ANHYDRASES; CELL HYPOXIA; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 84862812276     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.32     Document Type: Article

References (65)

1. Achison M, Hupp TR (2003) Hypoxia attenuates the p53 response to cellular damage. Oncogene 22(22): 3431-3440 (Pubitemid 36713741)
2. Bartelink H, Horiot JC, Poortmans P, Struikmans H, Van den Bogaert W, Barillot I, Fourquet A, Borger J, Jager J, Hoogenraad W, Collette L, Pierart M (2001) Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 345(19): 1378-1387
3. Bartosova M, Parkkila S, Pohlodek K, Karttunen TJ, Galbavy S, Mucha V, Harris AL, Pastorek J, Pastorekova S (2002) Expression of carbonic anhydrase IX in breast is associated with malignant tissues and is related to overexpression of c-erbB2. J Pathol 197(3): 314-321 (Pubitemid 34778301)
4. Bofin AM, Ytterhus B, Hagmar BM (2003) TOP2A and HER-2 gene amplification in fine needle aspirates from breast carcinomas. Cytopathology 14(6): 314-319 (Pubitemid 37521861)
5. Brennan DJ, Jirstrom K, Kronblad A, Millikan RC, Landberg G, Duffy MJ, Ryden L, Gallagher WM, O'Brien SL (2006) CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance. Clin Cancer Res 12(21): 6421-6431 (Pubitemid 44799714)
6. Bui MH, Visapaa H, Seligson D, Kim H, Han KR, Huang Y, Horvath S, Stanbridge EJ, Palotie A, Figlin RA, Belldegrun AS (2004) Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol 171(6 Pt 1): 2461-2466 (Pubitemid 38625515)
7. Chia SK, Wykoff CC, Watson PH, Han C, Leek RD, Pastorek J, Gatter KC, Ratcliffe P, Harris AL (2001) Prognostic significance of a novel hypoxiaregulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol 19(16): 3660-3668 (Pubitemid 32786278)
8. Cooper C, Liu GY, Niu YL, Santos S, Murphy LC, Watson PH (2004) Intermittent hypoxia induces proteasome-dependent down-regulation of estrogen receptor alpha in human breast carcinoma. Clin Cancer Res 10(24): 8720-8727 (Pubitemid 40053441)
9. Dang CV, Semenza GL (1999) Oncogenic alterations of metabolism. Trends Biochem Sci 24(2): 68-72 (Pubitemid 29346576)
10. Davies KJ, Doroshow JH (1986) Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J Biol Chem 261(7): 3060-3067 (Pubitemid 17204909)
11. Dewhirst MW, Cao Y, Moeller B (2008) Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 8(6): 425-437 (Pubitemid 351744964)
12. Doroshow JH, Davies KJ (1986) Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. J Biol Chem 261(7): 3068-3074 (Pubitemid 17204910)
13. Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL (2005) Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol 23(34): 8597-8605 (Pubitemid 46211501)
14. Dressler LG, Berry DA, Broadwater G, Cowan D, Cox K, Griffin S, Miller A, Tse J, Novotny D, Persons DL, Barcos M, Henderson IC, Liu ET, Thor A, Budman D, Muss H, Norton L, Hayes DF (2005) Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol 23(19): 4287-4297 (Pubitemid 46207003)
15. Frederiksen LJ, Siemens DR, Heaton JP, Maxwell LR, Adams MA, Graham CH (2003) Hypoxia induced resistance to doxorubicin in prostate cancer cells is inhibited by low concentrations of glyceryl trinitrate. J Urol 170(3): 1003-1007 (Pubitemid 36999621)
16. Freyer JP, Tustanoff E, Franko AJ, Sutherland RM (1984) In situ oxygen consumption rates of cells in V-79 multicellular spheroids during growth. J Cell Physiol 118(1): 53-61 (Pubitemid 14184343)
17. Generali D, Fox SB, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield SM, Bruzzi P, Bersiga A, Allevi G, Milani M, Aguggini S, Dogliotti L, Bottini A, Harris AL (2006) Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer. Endocr Relat Cancer 13(3): 921-930 (Pubitemid 44763267)
18. Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U, Bruzzi P (2008) HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 100(1): 14-20 (Pubitemid 351767337)
19. Gerweck LE, Seetharaman K (1996) Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res 56(6): 1194-1198 (Pubitemid 26080953)
20. Grau C, Overgaard J (1992) Effect of etoposide, carmustine, vincristine, 5-fluorouracil, or methotrexate on radiobiologically oxic and hypoxic cells in a C3H mouse mammary carcinoma in situ. Cancer Chemother Pharmacol 30(4): 277-280
21. Harris AL (2002) Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2(1): 38-47 (Pubitemid 37328806)
22. Hershman D, Neugut AI, Jacobson JS, Wang J, Tsai WY, McBride R, Bennett CL, Grann VR (2007) Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 99(3): 196-205
23. Honig S (1996) Treatment of metastatic disease: hormonal and chemotherapy. In: Diseases of the Breast, Harris J, Lippman M, Morrow M (eds). pp 669-734. Lippincott-Raven: Philadelphia
24. Hui EP, Chan AT, Pezzella F, Turley H, To KF, Poon TC, Zee B, Mo F, Teo PM, Huang DP, Gatter KC, Johnson PJ, Harris AL (2002) Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 8(8): 2595-2604 (Pubitemid 34856346)
25. Hurny C, Bernhard J, Coates AS, Castiglione-Gertsch M, Peterson HF, Gelber RD, Forbes JF, Rudenstam CM, Simoncini E, Crivellari D, Goldhirsch A, Senn HJ (1996) Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. Lancet 347(9011): 1279-1284 (Pubitemid 26137790)
26. Hussain SA, Palmer DH, Ganesan R, Hiller L, Gregory J, Murray PG, Pastorek J, Young L, James ND (2004) Carbonic anhydrase IX, a markerof hypoxia: correlation with clinical outcome in transitional cell carcinoma of the bladder. Oncol Rep 11(5): 1005-1010
27. Jarvinen TA, Tanner M, Rantanen V, Barlund M, Borg A, Grenman S, Isola J (2000) Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 156(3): 839-847 (Pubitemid 30626942)
28. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58(2): 71-96 (Pubitemid 351521864)
29. Jensen EV, Cheng G, Palmieri C, Saji S, Makela S, Van Noorden S, Wahlstrom T, Warner M, Coombes RC, Gustafsson JA (2001) Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci USA 98(26): 15197-15202 (Pubitemid 34019150)
30. Kim SJ, Rabbani ZN, Dewhirst MW, Vujaskovic Z, Vollmer RT, Schreiber EG, Oosterwijk E, Kelley MJ (2005) Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer 49(3): 325-335 (Pubitemid 41139145)
31. Kim SJ, Rabbani ZN, Vollmer RT, Schreiber EG, Oosterwijk E, Dewhirst MW, Vujaskovic Z, Kelley MJ (2004) Carbonic anhydrase IX in early-stage non-small cell lung cancer. Clin Cancer Res 10(23): 7925-7933 (Pubitemid 39587532)
32. Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos K, Pastorek J, Wykoff CC, Gatter KC, Harris AL (2001) Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res 7(11): 3399-3403 (Pubitemid 33069972)
33. Lindley C (1997) In: Pharmacotherapy: a Pathophysiologic Approach DiPiro J, Talbert R, Yee G (eds). pp 2467-2497. Appleton & Lange: Stamford, CT
34. Lindskog S (1997) Structure and mechanism of carbonic anhydrase. Pharmacol Ther 74(1): 1-20 (Pubitemid 27337350)
35. Loncaster JA, Harris AL, Davidson SE, Logue JP, Hunter RD, Wycoff CC, Pastorek J, Ratcliffe PJ, Stratford IJ, West CM (2001) Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 61(17): 6394-6399 (Pubitemid 32783244)
36. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson IC. (1994) c-erbB-2 expression and response to adjuvant therapy in women with nodepositive early breast cancer. N Engl J Med 330(18): 1260-1266
37. Navalta JW, McFarlin BK, Lyons TS (2010) Does exercise really induce lymphocyte apoptosis? Front Biosci (Elite Ed) 2: 478-488
38. Olive PL, Aquino-Parsons C, MacPhail SH, Liao SY, Raleigh JA, Lerman MI, Stanbridge EJ (2001) Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res 61(24): 8924-8929 (Pubitemid 34013910)
39. Olsen KE, Knudsen H, Rasmussen BB, Balslev E, Knoop A, Ejlertsen B, Nielsen KV, Schonau A, Overgaard J (2004) Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Acta Oncol 43(1): 35-42 (Pubitemid 38283171)
40. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL, Wolmark N (1998) erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90(18): 1361-1370 (Pubitemid 28439960)
41. Pastorek J, Pastorekova S, Callebaut I, Mornon JP, Zelnik V, Opavsky R, Zat'ovicova M, Liao S, Portetelle D, Stanbridge EJ, Zavada J, Burny A, Kettmann R (1994) Cloning and characterization of MN, a human tumorassociated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene 9(10): 2877-2888
42. Pastorekova S, Zavadova Z, Kostal M, Babusikova O, Zavada J (1992) A novel quasi-viral agent, MaTu, is a two-component system. Virology 187(2): 620-626
43. Pauletti G, Godolphin W, Press MF, Slamon DJ (1996) Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13(1): 63-72 (Pubitemid 26248546)
44. Piccart-Gebhart MJ (2006) Anthracyclines and the tailoring of treatment for early breast cancer. N Engl J Med 354(20): 2177-2179 (Pubitemid 43736618)
45. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH (2007) Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25(25): 3808-3815 (Pubitemid 47477254)
46. Pritchard KI, Shepherd LE, O'Malley FP, Andrulis IL, Tu D, Bramwell VH, Levine MN (2006) HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354(20): 2103-2111 (Pubitemid 43736610)
47. Ranson MR, Carmichael J, O'Byrne K, Stewart S, Smith D, Howell A (1997) Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 15(10): 3185-3191 (Pubitemid 27419330)
48. Ries L, Eisner M (2007) Cancer of the Female Breast. In: SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics, Ries L, Young J, Keel G, Eisner M, Lin Y, Horner M (eds). Chapter 13. National Cancer Institute, SEER Program: Bethesda, MD, NIH Pub. No. 07-6215
49. Secomb TW, Hsu R, Ong ET, Gross JF, Dewhirst MW (1995) Analysis of the effects of oxygen supply and demand on hypoxic fraction in tumors. Acta Oncol 34(3): 313-316
50. Shannon AM, Bouchier-Hayes DJ, Condron CM, Toomey D (2003) Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev 29(4): 297-307 (Pubitemid 37069660)
51. Smith K, Houlbrook S, Greenall M, Carmichael J, Harris AL (1993) Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene 8(4): 933-938 (Pubitemid 23087425)
52. Song X, Liu X, Chi W, Liu Y, Wei L, Wang X, Yu J (2006) Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Cancer Chemother Pharmacol 58(6): 776-784 (Pubitemid 44351258)
53. Span PN, Bussink J, Manders P, Beex LV, Sweep CG (2003) Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: association with treatment outcome. Br J Cancer 89(2): 271-276 (Pubitemid 36976315)
54. Svastova E, Hulikova A, Rafajova M, Zat'ovicova M, Gibadulinova A, Casini A, Cecchi A, Scozzafava A, Supuran CT, Pastorek J, Pastorekova S (2004) Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett 577(3): 439-445 (Pubitemid 39535327)
55. Swinson DE, Jones JL, Richardson D, Wykoff C, Turley H, Pastorek J, Taub N, Harris AL, O'Byrne KJ (2003) Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol 21(3): 473-482 (Pubitemid 46613490)
56. Tan EY, Yan M, Campo L, Han C, Takano E, Turley H, Candiloro I, Pezzella F, Gatter KC, Millar EK, O'Toole SA, McNeil CM, Crea P, Segara D, Sutherland RL, Harris AL, Fox SB (2009) The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. Br J Cancer 100(2): 405-411
57. Teicher BA, Holden SA, al-Achi A, Herman TS (1990) Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res 50(11): 3339-3344 (Pubitemid 20190142)
58. Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, Barcos M, Cirrincione C, Edgerton S, Allred C, Norton L, Liu ET (1998) erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90(18): 1346-1360 (Pubitemid 28439959)
59. Vaupel P, Briest S, Hockel M (2002) Hypoxia in breast cancer: pathogenesis, characterization and biological/therapeutic implications. Wien Med Wochenschr 152(13-14): 334-342 (Pubitemid 34824207)
60. Winer E, Morrow M, Osborne C (2001) Malignant tumors of the breast. In: Cancer: Principles and Practice of Oncology, DeVita V, Hellman S, Rosenberg R (eds), pp 1651-1717. Lippincott Williams & Wilkins: Philadelphia, PA
61. Withoff S, De Jong S, De Vries EG, Mulder NH (1996a) Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance (review). Anticancer Res 16(4A): 1867-1880 (Pubitemid 26270698)
62. Withoff S, Keith WN, Knol AJ, Coutts JC, Hoare SF, Mulder NH, de Vries EG (1996b) Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel. Br J Cancer 74(4): 502-507 (Pubitemid 26279042)
63. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL (2000) Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60(24): 7075-7083 (Pubitemid 32059187)
64. Yoshiba S, Ito D, Nagumo T, Shirota T, Hatori M, Shintani S (2009) Hypoxia induces resistance to 5-fluorouracil in oral cancer cells via G(1) phase cell cycle arrest. Oral Oncol 45(2): 109-115
65. Zavada J, Zavadova Z, Pastorekova S, Ciampor F, Pastorek J, Zelnik V (1993) Expression of MaTu-MN protein in human tumor cultures and in clinical specimens. Int J Cancer 54(2): 268-274 (Pubitemid 23154893)